Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4742867
Max Phase: Preclinical
Molecular Formula: C56H70Cl2N8O14
Molecular Weight: 1150.12
Molecule Type: Unknown
Associated Items:
ID: ALA4742867
Max Phase: Preclinical
Molecular Formula: C56H70Cl2N8O14
Molecular Weight: 1150.12
Molecule Type: Unknown
Associated Items:
Canonical SMILES: COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(CCCCCCOCCOCCOCCOCCOCCOCC(=O)Nc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)c(OC)cc23)c(Cl)cc1Cl
Standard InChI: InChI=1S/C56H70Cl2N8O14/c1-72-47-34-45(41(57)32-42(47)58)62-53-38(35-59)36-60-44-33-49(48(73-2)31-40(44)53)80-20-8-14-65-17-15-64(16-18-65)13-5-3-4-6-19-74-21-22-75-23-24-76-25-26-77-27-28-78-29-30-79-37-51(68)61-43-10-7-9-39-52(43)56(71)66(55(39)70)46-11-12-50(67)63-54(46)69/h7,9-10,31-34,36,46H,3-6,8,11-30,37H2,1-2H3,(H,60,62)(H,61,68)(H,63,67,69)
Standard InChI Key: RBQXHLBIJMHVHI-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1150.12 | Molecular Weight (Monoisotopic): 1148.4389 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Kargbo RB.. (2020) Breakthrough in Degradation of BCR-ABL Fusion Protein for the Treatment of Cancer., 11 (12.0): [PMID:33335652] [10.1021/acsmedchemlett.0c00587] |
Source(1):